Association of preexisting interstitial lung abnormalities with immune checkpoint inhibitor–induced interstitial lung disease among patients with nonlung cancers
K Shimoji, T Masuda, K Yamaguchi… - JAMA Network …, 2020 - jamanetwork.com
Importance Immune checkpoint inhibitor–induced interstitial lung disease (ICI-ILD) is
clinically serious and life-threatening. Preexisting interstitial lung abnormalities have been …
clinically serious and life-threatening. Preexisting interstitial lung abnormalities have been …
Drug-related pneumonitis induced by osimertinib as first-line treatment for epidermal growth factor receptor mutation-positive non-small cell lung cancer: a real-world …
Y Sato, H Sumikawa, R Shibaki, T Morimoto, Y Sakata… - Chest, 2022 - Elsevier
Background Osimertinib has demonstrated impressive efficacy as a first-line treatment for
patients with advanced epidermal growth factor receptor (EGFR) mutation-positive (m+) lung …
patients with advanced epidermal growth factor receptor (EGFR) mutation-positive (m+) lung …
Interstitial lung abnormalities at CT: subtypes, clinical significance, and associations with lung cancer
A Hata, T Hino, M Yanagawa, M Nishino, T Hida… - Radiographics, 2022 - pubs.rsna.org
Interstitial lung abnormality (ILA) is defined as an interstitial change detected incidentally on
CT images. It is seen in 4%–9% of smokers and 2%–7% of nonsmokers. ILA has a tendency …
CT images. It is seen in 4%–9% of smokers and 2%–7% of nonsmokers. ILA has a tendency …
Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian …
S Hoa, L Laaouad, J Roberts, D Ennis, C Ye… - Cancer Immunology …, 2021 - Springer
Background Limited data are available on the safety and efficacy of immune checkpoint
inhibitors (ICI) in patients with preexisting autoimmune diseases (PAD). Methods …
inhibitors (ICI) in patients with preexisting autoimmune diseases (PAD). Methods …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
R Govindan, C Aggarwal, SJ Antonia… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Immunotherapy has transformed lung cancer care in recent years. In addition to providing
durable responses and prolonged survival outcomes for a subset of patients with heavily …
durable responses and prolonged survival outcomes for a subset of patients with heavily …
Outcome and risk factor of immune‐related adverse events and pneumonitis in patients with advanced or postoperative recurrent non‐small cell lung cancer treated …
T Isono, N Kagiyama, K Takano, C Hosoda… - Thoracic …, 2021 - Wiley Online Library
Background Non‐small cell lung cancer (NSCLC) patients with pre‐existing respiratory
diseases have been excluded in clinical trials of immune checkpoint inhibitor (ICI) therapy …
diseases have been excluded in clinical trials of immune checkpoint inhibitor (ICI) therapy …
Risk factors for immune checkpoint inhibitor-related pneumonitis in cancer patients: a systemic review and meta-analysis
P Zhou, X Zhao, G Wang - Respiration, 2022 - karger.com
Abstract Background: Immune checkpoint inhibitors (ICIs) can lead to one of the common
and quite serious immune-related adverse events (irAEs) in a real-world setting, namely …
and quite serious immune-related adverse events (irAEs) in a real-world setting, namely …
Management of lung cancer in the patient with interstitial lung disease
AJ Frank, I Dagogo-Jack, IA Dobre, S Tait… - The …, 2023 - academic.oup.com
Patients with interstitial lung disease (ILD), especially those with pulmonary fibrosis, are at
increased risk of developing lung cancer. Management of lung cancer in patients with ILD is …
increased risk of developing lung cancer. Management of lung cancer in patients with ILD is …
Impact of interstitial lung abnormalities on postoperative pulmonary complications and survival of lung cancer
Y Im, MP Chung, KS Lee, J Han, MJ Chung, HK Kim… - Thorax, 2023 - thorax.bmj.com
Background Interstitial lung abnormalities (ILAs) are associated with the risk of lung cancer
and its mortality. However, the impact of ILA on treatment-related complications and survival …
and its mortality. However, the impact of ILA on treatment-related complications and survival …
Biomarkers and risk factors for the early prediction of immune-related adverse events: a review
Y Zhang, X Zhang, W Li, Y Du, W Hu… - Human Vaccines & …, 2022 - Taylor & Francis
In recent years, immunotherapy has been widely used to treat patients with malignant
tumors. While immune checkpoint inhibitors (ICIs) significantly improve the prognosis of …
tumors. While immune checkpoint inhibitors (ICIs) significantly improve the prognosis of …